Oncology
Overview
Invicro uniquely combines operational excellence with extensive scientific and medical expertise. Our goal is to drive the advancement of translational cancer research, aid in cancer drug development and develop imaging methods and tools that enable precision medicine. We have experience working with a wide range of therapeutics, including small molecules, peptides, antibodies, multi-specific proteins, CAR-T cells, and many more. Preclinically and clinically, Invicro offers a wide variety of oncology biomarker solutions, including:
- Central imaging core lab for Phase 0-IV clinical studies
- Preclinical/Clinical novel molecular imaging tracers
- In vitro, in vivo, and ex vivo techniques spanning from preclinical to clinical
- Core histology, multiplex Immunohistochemistry (IHC) / Immunofluorescence (IF), Quanticell™ high sensitivity immunohistochemistry (IHC), RNAScope® ISH
- Qualitative and quantitative image analytics for radiology and pathology studies
Capabilities
Clinical Core Lab
Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:
- Segmentation
- Image co-registration
- Radiation dosimetry
- Mechanistic pharmacokinetic modeling including PBPK modeling
- Tracer kinetic modeling
- Radiomics
- Imaged-based machine learning
- Full service independent blind reads or collect and hold capabilities
- Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC
Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.
- Focal adhesion kinase inhibitor GSK2256098 (Neuro Oncol. 2018 May 17)
- Lapatinib (EJNMMI Res. 2015 Apr 30;5:30)
Quantitative Oncology Analytics
The medical image analysis team supports standard analysis of FDG PET imaging, including PERCIST and other SUV-based metrics, metabolic tumor volume and total lesion glycolysis. The image analysis team also specializes in developing and applying a broad range of tools to support advanced quantitative oncology tracer characterization and analytics across a broad range of modalities and studies. Some examples include:
- Powerful, multi-modal tumor and organ Segmentation tools
- A range of flexible Biomathematical Modeling tools
- Dosimetry calculations across radionuclide, administration route, and species
- Integrated Radiomics pipelines using standard and custom feature vectors
- Preclinical and clinical support for Tracer Characterization
- Sophisticated batch Image Triage and preprocessing methods
For more information, check out some of our most popular case studies. A full list is also available in our case studies section!
Advanced Pathology Services
Invicro provides comprehensive pathology services to support all phases of oncology and immuno-oncology drug development applications. Our multidisciplinary team of scientific and medical experts provide a unique approach by leveraging cutting-edge and proprietary molecular pathology detection and analysis technologies. From experimental design to developing and validating biomarker assays, we deliver actionable insights in both a research and CAP-CLIA environment. Our capabilities include:
- Core histology
- Specialty stains
- Multiplex Immunohistochemistry (IHC) / Immunofluorescence (IF)
- RNAScope® ISH
- Assay development and validation
- Quanticell™ High sensitivity Immunohistochemistry IHC)
- Pathologist interpretation
- Whole Side Imaging (WSI)
- Image analysis
- Companion Diagnostic (CDx) development
- Digital biomarker development
Radiochemistry
Invicros radiochemistry team has experience with almost all commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:
- A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ
- Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
- 18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
- Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteer
Rodent Models
We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:
- Syngeneic models
- Human xenograft tumors in immunocompromised mice
- Humanized mouse models
- GEMM mouse model
We also work with larger species including canine, porcine, and non-human primates (NHP).
Modalities
in vivo
- PET
- SPECT
- CT
- MR
- US
- Bioluminescence
- Fluorescence Molecular Tomography (FMT)
ex vivo
- Cryo-fluorescence tomography (CFT)
- ex vivo fluorescence reflectance imaging
- Autoradiography & micro-autoradiography
- Core histology, multiplex Immunohistochemistry (IHC) / Immunofluorescence (IF), Quanticell™ high sensitivity immunohistochemistry (IHC), RNAScope® ISH
- Gamma counting
- Flow cytometry
- Clinical chemistry
- CBC analysis
- Urinalysis
in vitro & chemistry
- Tissue homogenate binding
- Cell culture
- Cell binding and competition
- Internalization
- ELISA
- Western blots
- Targeted radiotherapeutics